View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 27, 2020

Vela Diagnostics’ Covid-19 detection test receives CE Mark

Vela Diagnostics has received the CE Mark for the manual version of the ViroKey SARS-CoV-2 RT-PCR Covid-19 detection test for in vitro diagnostic use.


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

Follow the latest updates of the outbreak on our timeline


Vela Diagnostics has received the CE Mark for the manual version of the ViroKey SARS-CoV-2 RT-PCR Covid-19 detection test for in vitro diagnostic use.

The probe-based reverse transcription PCR test detects SARS-CoV-2 virus in patients suspected of Covid-19.

It detects SARS-CoV-2 by targeting conserved regions of the SARS-CoV-2 genome. The manual version of the assay allows quick adoption of the Covid-19 detection test by laboratories with existing Applied Biosystems 7500 Fast Dx (ABI 7500 Fast Dx) instruments.

Vela Diagnostics acting CEO and Board chairman Sam Dajani said: “The CE mark enables Vela Diagnostics to expand Covid-19 testing capacity in Europe, where there is an urgent need to identify individuals infected with SARS-CoV-2.”

In addition, the company has developed an automated version of the test. Vela Diagnostics is expected to complete CE-IVD registration by the end of the month.

The automated ViroKey SARS-CoV-2 RT-PCR Test is optimised for a workflow, consisting of the Sentosa SX101 instrument combined with the Sentosa SA201 instrument or the ABI 7500 Fast Dx.

Last week, Vela Diagnostics was contracted by the Biomedical Advanced Research and Development Authority (BARDA) in the US to support the development of its Covid-19 tests. This $225,000 contract will allow the company to carry out verification and clinical validation of the ViroKey SARS-CoV-2 RT-PCR Test.

Meanwhile, more than 2,971,831 Covid-19 cases have been reported globally with the fatality rate reaching up to 206,553.

The US, which is now the epicentre of the pandemic, has recorded over 965,910 confirmed cases and 54,876 deaths.

A few of the hardest-hit European countries like Spain, Italy and France have seen a slight drop in the number of Covid-19 cases over the past two weeks.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network